Quick Answer
Monte Rosa Therapeutics, Inc. reported Net Income Loss of -$38.63 million for the year ending 2025.
- Monte Rosa Therapeutics, Inc. showed an increase of +46.9% in Net Income Loss from 2024 to 2025.
- This data is from Monte Rosa Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$4.30 million | Q2 2020: -$5.36 million | Q3 2020: -$6.56 million | Q1 2021: -$12.28 million | Q2 2021: -$18.41 million | Q3 2021: -$19.84 million | Q1 2022: -$23.93 million | Q2 2022: -$26.47 million | Q3 2022: -$27.32 million | Q1 2023: -$32.04 million | Q2 2023: -$35.18 million | Q3 2023: -$34.88 million | Q1 2024: -$31.97 million | Q2 2024: -$30.31 million | Q3 2024: -$23.86 million | Q1 2025: $46.89 million | Q2 2025: -$12.30 million | Q3 2025: -$27.08 million.
- Over the full 6 years of available data (2020 to 2025), Monte Rosa Therapeutics, Inc.'s Net Income Loss has declined by 7.7%.
- Historical annual values: Fiscal year 2025: -$38.63 million | Fiscal year 2024: -$72.70 million | Fiscal year 2023: -$135.35 million | Fiscal year 2022: -$108.50 million | Fiscal year 2021: -$73.96 million | Fiscal year 2020: -$35.88 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: